|
gptkbp:instanceOf
|
gptkb:drug
small molecule
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2018
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01ED50
|
|
gptkbp:bioavailability
|
81%
|
|
gptkbp:brand
|
gptkb:Lorbrena
gptkb:Lorviqua
|
|
gptkbp:CASNumber
|
1392817-72-1
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:eliminationHalfLife
|
23.6 hours
|
|
gptkbp:hasMolecularFormula
|
C21H19FN6O2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
lorlatinib
|
|
gptkbp:indication
|
ALK-positive metastatic non-small cell lung cancer
ROS1-positive metastatic non-small cell lung cancer
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
gptkb:receptor_tyrosine_kinase
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
|
|
gptkbp:molecularWeight
|
406.42 g/mol
|
|
gptkbp:pregnancyCategory
|
Not recommended
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:familial_hypercholesterolemia
edema
weight gain
peripheral neuropathy
cognitive effects
hypertriglyceridemia
mood effects
|
|
gptkbp:target
|
gptkb:ALK
ROS1
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
|
|
gptkbp:bfsParent
|
gptkb:ALK_rearrangement
|
|
gptkbp:bfsLayer
|
5
|